• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Application of French prognostic score to patients with International Prognostic Scoring System intermediate-2 or high risk myelodysplastic syndromes treated with 5-azacitidine is able to predict overall survival and rate of response.

作者信息

Breccia Massimo, Loglisci Giuseppina, Cannella Laura, Finsinger Paola, Mancini Marco, Serrao Alessandra, Santopietro Michelina, Salaroli Adriano, Alimena Giuliana

出版信息

Leuk Lymphoma. 2012 May;53(5):985-6. doi: 10.3109/10428194.2011.643408. Epub 2012 Jan 11.

DOI:10.3109/10428194.2011.643408
PMID:22112007
Abstract
摘要

相似文献

1
Application of French prognostic score to patients with International Prognostic Scoring System intermediate-2 or high risk myelodysplastic syndromes treated with 5-azacitidine is able to predict overall survival and rate of response.将法国预后评分应用于接受5-氮杂胞苷治疗的国际预后评分系统中危-2或高危骨髓增生异常综合征患者，能够预测总生存期和缓解率。
Leuk Lymphoma. 2012 May;53(5):985-6. doi: 10.3109/10428194.2011.643408. Epub 2012 Jan 11.
2
Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes.比较阿扎胞苷治疗骨髓增生异常综合征患者中修订后的国际预后评分系统和法国预后评分系统的预后预测价值。
Br J Haematol. 2014 Aug;166(3):352-9. doi: 10.1111/bjh.12884. Epub 2014 Apr 9.
3
Comparison of various criteria in predicting treatment response and prognosis of patients with myelodysplastic syndrome treated with azacitidine.比较各种标准在预测接受阿扎胞苷治疗的骨髓增生异常综合征患者的治疗反应和预后中的作用。
Ann Hematol. 2010 Jan;89(1):15-23. doi: 10.1007/s00277-009-0771-1. Epub 2009 Jun 19.
4
Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides.用于预测接受氮杂核苷治疗的高危骨髓增生异常综合征患者预后的风险分层工具比较
Leukemia. 2016 Mar;30(3):649-57. doi: 10.1038/leu.2015.283. Epub 2015 Oct 14.
5
Efficacy and safety of a 5-day regimen of azacitidine for patients with high-risk myelodysplastic syndromes.阿扎胞苷5天方案治疗高危骨髓增生异常综合征患者的疗效与安全性。
Eur J Haematol. 2016 Sep;97(3):228-31. doi: 10.1111/ejh.12709. Epub 2016 Jan 3.
6
Results of treatment with azacitidine in patients aged ≥ 75 years included in the Spanish Registry of Myelodysplastic Syndromes.西班牙骨髓增生异常综合征登记处纳入的年龄≥75岁患者接受阿扎胞苷治疗的结果。
Leuk Lymphoma. 2014 Jun;55(6):1300-3. doi: 10.3109/10428194.2013.834532. Epub 2013 Sep 16.
7
Practical use of azacitidine in higher-risk myelodysplastic syndromes: an expert panel opinion.阿扎胞苷在高危骨髓增生异常综合征中的实际应用：专家小组意见。
Leuk Res. 2010 Nov;34(11):1410-6. doi: 10.1016/j.leukres.2010.05.021. Epub 2010 Jul 6.
8
Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group.阿扎胞苷治疗骨髓增生异常综合征（MDS）患者：德国 MDS 研究组的实用建议。
Ann Hematol. 2010 Sep;89(9):841-50. doi: 10.1007/s00277-010-1015-0. Epub 2010 Jun 22.
9
Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.高危骨髓增生异常综合征和急性髓系白血病患者序贯使用阿扎胞苷和来那度胺：一项单臂1/2期研究。
Lancet Haematol. 2015 Jan;2(1):e12-20. doi: 10.1016/S2352-3026(14)00026-X. Epub 2014 Dec 22.
10
Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry.阿扎胞苷治疗未选择高危骨髓增生异常综合征的疗效：来自西班牙登记处的数据。
Leukemia. 2015 Sep;29(9):1875-81. doi: 10.1038/leu.2015.115. Epub 2015 May 6.

引用本文的文献

1
More is less, less is more, or does it really matter? The curious case of impact of azacitidine administration schedules on outcomes in patients with myelodysplastic syndromes.多即是少，少即是多，还是这真的重要？阿扎胞苷给药方案对骨髓增生异常综合征患者预后影响的奇特案例。
BMC Hematol. 2018 Feb 1;18:4. doi: 10.1186/s12878-018-0095-2. eCollection 2018.
2
Systematic review of azacitidine regimens in myelodysplastic syndrome and acute myeloid leukemia.阿扎胞苷方案治疗骨髓增生异常综合征和急性髓系白血病的系统评价
BMC Hematol. 2018 Jan 31;18:3. doi: 10.1186/s12878-017-0094-8. eCollection 2018.
3
Azacitidine: A Review in Myelodysplastic Syndromes and Acute Myeloid Leukaemia.
阿扎胞苷：在骨髓增生异常综合征和急性髓系白血病中的综述。
Drugs. 2016 May;76(8):889-900. doi: 10.1007/s40265-016-0585-0.
4
Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides.用于预测接受氮杂核苷治疗的高危骨髓增生异常综合征患者预后的风险分层工具比较
Leukemia. 2016 Mar;30(3):649-57. doi: 10.1038/leu.2015.283. Epub 2015 Oct 14.
5
TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.TET2突变可预测骨髓增生异常综合征患者对去甲基化药物的反应。
Blood. 2014 Oct 23;124(17):2705-12. doi: 10.1182/blood-2014-06-582809. Epub 2014 Sep 15.
6
Stopping higher-risk myelodysplastic syndrome in its tracks.在早期阶段阻止高风险骨髓增生异常综合征。
Curr Hematol Malig Rep. 2014 Dec;9(4):421-31. doi: 10.1007/s11899-014-0234-1.
7
Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes.比较阿扎胞苷治疗骨髓增生异常综合征患者中修订后的国际预后评分系统和法国预后评分系统的预后预测价值。
Br J Haematol. 2014 Aug;166(3):352-9. doi: 10.1111/bjh.12884. Epub 2014 Apr 9.
8
Predicting response to epigenetic therapy.预测表观遗传学治疗的反应。
J Clin Invest. 2014 Jan;124(1):47-55. doi: 10.1172/JCI69737. Epub 2014 Jan 2.
9
Current therapy of myelodysplastic syndromes.骨髓增生异常综合征的当前治疗。
Blood Rev. 2013 Sep;27(5):243-59. doi: 10.1016/j.blre.2013.07.003. Epub 2013 Jul 27.
10
Concise drug review: azacitidine and decitabine.简明药物评论：阿扎胞苷和地西他滨。
Oncologist. 2013;18(5):619-24. doi: 10.1634/theoncologist.2012-0465. Epub 2013 May 13.